BofA raised the firm’s price target on Regeneron (REGN) to $650 from $605 and keeps an Underperform rating on the shares. While shares have traded positively following last week’s update on Regeneron and Sanofi’s (SNY) Dupixent data in COPD, the firm said its call with a key opinion leader about the data and what it could mean for the COPD treatment paradigm lead them to maintain the view that "there is still more wood to chop." BofA remain sidelined on Regeneron as it thinks the future of the Eylea franchise remains challenging and the oncology franchise may not mature in time to offset losses.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
- Regeneron resumed with a Buy at Erste Group
- Immuneering appoints Harold Brakewood as CBO
- Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration
- Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
